Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OBI 3424

Next Previous
Drug Profile

OBI 3424

Alternative Names: AST-3424; OBI-3424; TH-3424

Latest Information Update: 08 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Threshold Pharmaceuticals
  • Developer Ascentawits Pharmaceuticals; National Cancer Institute (USA); OBI Pharma
  • Class Antineoplastics; Aziridines; Benzamides; Benzene derivatives; Ethers; Nitro compounds; Phosphorus compounds; Small molecules
  • Mechanism of Action Alkylating agents; DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor cell lymphoblastic leukaemia-lymphoma; Liver cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Precursor T-cell lymphoblastic leukaemia-lymphoma
  • Phase I/II Liver cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 25 Apr 2025 Pharmacodynamic data from a preclinical trial in Solid tumors presented at the 116th Annual Meeting of the American Association for Cancer Research(AACR-2025)
  • 25 Apr 2025 Pharmacodynamics and adverse events data from preclinical trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 27 Sep 2024 Efficacy data from a phase I/II trial in Liver cancer released by Ascentawits Pharma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top